SHANGHAI and NEW YORK, Jan. 8,
2019 /PRNewswire/ -- Cellular Biomedicine Group Inc.
(NASDAQ: CBMG) ("CBMG" or the "Company"), a biopharmaceutical
firm engaged in the development of immunotherapies for cancer and
stem cell therapies for degenerative diseases, today announces the
initiation of patient recruitment to support the study of anti-BCMA
CAR-T therapy targeting relapsed and refractory Multiple Myeloma in
China.
"China has seen a substantial
increase in the incidence of Multiple Myeloma. As a drug
development company, BCMA is the first of multiple assets that CBMG
is advancing amongst our oncology pipeline beyond our collaboration
with a global leader in cell therapy," commented Tony (Bizuo) Liu,
Chief Executive Officer of the Company. "We plan to provide updates
in the near future on the progress of our other proprietary
technologies, including anti-CD22 and anti-CD20 CAR-T targeting
relapsed Acute Lymphoblastic Leukemia (ALL) and Diffuse Large
B-cell Lymphoma (DLBCL) patients post anti-CD19 CAR-T treatment,
Alpha Fetoprotein T-cell Receptor (AFP-TCR-T) for Hepatocellular
Carcinoma, and next generation Tumor Infiltrating Lymphocytes (TIL)
for the treatment of non-small cell lung cancer (NSCLC) and other
solid tumor indications. We hope to be able to provide
expeditious, safe and effective therapies to cancer patients who
currently have limited treatment options."
About the Study
This Phase I clinical study will
enroll 22 patients to evaluate the safety and efficacy of C-CAR088
(anti-BCMA Chimeric Antigen Receptor T-Cell therapy) in patients
with relapsed and/or refractory Multiple Myeloma.
About Multiple Myeloma in China
It is estimated that there are
27,800 new cases of Multiple Myeloma, a cancer derived from plasma
cells, diagnosed in China each
year. With the acceleration of the aging process in
China, it is predicted that
Multiple Myeloma, with a rapid growth in incidence, will become one
of the more significant diseases that affect people's health in the
country. (Source: Blood Cancer J. 2014 Aug
15;4:e239. doi: 10.1038/bcj.2014.55)
About Cellular Biomedicine Group
Cellular
Biomedicine Group, Inc. (NASDAQ: CBMG)
develops proprietary cell therapies for the treatment of cancer and
degenerative diseases. We conduct immuno-oncology and stem cell
clinical trials in China using
products from our integrated GMP laboratory. Our GMP facilities in
China, consisting of 12
independent cell production lines, are designed and managed
according to both China and U.S.
GMP standards. Our Shanghai facility includes a "Joint
Laboratory of Cell Therapy" with GE Healthcare and a "Joint Cell
Therapy Technology Innovation and Application Center" with Thermo
Fisher Scientific, whose partnerships focus on improving
manufacturing processes for cell therapies. The CBMG pipeline
includes preclinical compounds targeting CD20-, CD22- and B-cell
maturation antigen (BCMA)-specific CAR-T compounds, and T-cell
receptor (TCR) and tumor infiltrating lymphocyte (TIL)
technologies. A Phase IIb trial in China for Rejoin® autologous Human
Adipose-derived Mesenchymal Progenitor Cell (haMPC) for the
treatment of Knee Osteoarthritis (KOA) as well as a Phase I trial
in China for AlloJoin™ (CBMG's
"Off-the-Shelf" haMPC) for the treatment of KOA are ongoing. CBMG
is included in the broad-market Russell 3000® Index and the
small-cap Russell 2000® Index, and the Loncar China BioPharma
index. To learn more about CBMG, please
visit www.cellbiomedgroup.com.
Forward-Looking Statements
Statements in this press
release relating to plans, strategies, trends, specific activities
or investments, and other statements that are not descriptions of
historical facts and may be forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995,
Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended.
Forward-looking information is inherently subject to risks and
uncertainties, and actual results could differ materially from
those currently anticipated due to a number of factors, which
include those regarding our ability to implement our plans,
strategies and objectives for future operations, including
regulatory approval of our IND applications, our plan to configure
part of our Shanghai facility with
GE Healthcare's FlexFactory platform, our ability to execute on our
obligations under the terms of our licensing and collaboration
arrangement with Novartis, our ability to execute on proposed new
products, services or development thereof, results of our clinical
research and development, regulatory infrastructure governing cell
therapy and cellular biopharmaceuticals, our ability to enter into
agreements with any necessary manufacturing, marketing and/or
distribution partners for purposes of commercialization, our
ability to seek intellectual property rights for our product
candidates, competition in the industry in which we operate,
overall market conditions, any statements or assumptions underlying
any of the foregoing and other risks detailed from time to time in
CBMG's reports filed with the Securities and Exchange Commission,
quarterly reports on form 10-Q, current reports on form 8-K and
annual reports on form 10-K. Forward-looking statements may be
identified by terms such as "may," "will," "expects," "plans,"
"intends," "estimates," "potential," or "continue," or similar
terms or the negative of these terms. Although CBMG believes the
expectations reflected in the forward-looking statements are
reasonable, it cannot guarantee that future results, levels of
activity, performance or achievements will be obtained. CBMG does
not have any obligation to update these forward-looking statements
other than as required by law.
Contacts:
Derrick C.
Li
Head of Strategy and Investor Relations, CBMG
+1 917 717 0994
derrick.li@cellbiomedgroup.com
View original
content:http://www.prnewswire.com/news-releases/cellular-biomedicine-group-initiates-patient-recruitment-for-clinical-trial-in-b-cell-maturation-antigen-anti-bcma-chimeric-antigen-receptor-t-cell-car-t-therapy-targeting-multiple-myeloma-mm-300775319.html
SOURCE Cellular Biomedicine Group